Pricing Log in Create free account
Friday 6 November 2026 Export VKTX’s income statement to Excel — free account

Viking Therapeutics, Inc.

VKTX Healthcare Biotechnology

EPS
−91.6%
Free cash flow
−47.0%

Quarter to September 2026, against a year earlier

26.87 1.08 +4.19%
Market cap
$3.3B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.15
Sold, $m 18.32
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — — — — —
Sell — 4 — — — — — 3 — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 3,290.00
Revenue ttm —
Net income ttm (627.19)
Free cash flow ttm (462.63)
Net debt Q (709.16)
Valuation
P/E 0.00
Forward P/E —
Price / sales 0.00
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.18
Financial health
Current ratio Q 7.27 (at or above 1.5: strong)
Debt / equity Q 0.43 (at or below 0.5: strong)
Interest coverage Q (2,126.27)
Growth
Revenue growth Q —
Operating income growth Q −89.84% (below 0%: shrinking)
EPS, this year −64.65% (below 0%: weak)
EPS, next year A +4.18%
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A −7.24% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 72.02%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 362 903 706 960
Receivables — — — —
Inventory — — — —
Other — — — —
367 907 716 973
2023 2024 2025 Q'26
Payables 8 10 53 82
ST’ Debt — — — —
Other — — — —
19 27 77 134

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 53.63% 21.20% 63.83%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.00 Actual −1.55

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.89 −1.38 Miss by 0.49
Q1 FY26 −0.95 −1.37 Miss by 0.42
Q2 FY26 −1.21 −1.10 Beat by 0.11
Q3 FY26 −1.00 −1.55 Miss by 0.55
Q4 FY26 −1.30 — Reports 10 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (1.37) (1.10) (1.55) — —
’25 (0.41) (0.58) (0.81) (1.38) (3.19)
’24 (0.26) (0.20) (0.22) (0.32) (1.01)
’23 (0.25) (0.19) (0.23) (0.25) (0.91)
’22 (0.21) (0.23) (0.21) (0.26) (0.90)
’21 (0.19) (0.20) (0.17) (0.16) (0.71)
’20 (0.13) (0.13) (0.13) (0.15) (0.54)
Fiscal quarters ending in the months shown.

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (114) (125) (138) — —
’25 (52) (47) (94) (85) (279)
’24 (6) (29) (22) (31) (88)
’23 (25) (11) (20) (18) (73)
’22 (11) (13) (13) (11) (48)
’21 (11) (13) (11) (12) (48)
’20 (4) (7) (5) (5) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (114) (125) (138) — —
’25 (52) (47) (94) (85) (279)
’24 (6) (29) (22) (31) (88)
’23 (25) (11) (20) (18) (73)
’22 (11) (13) (13) (11) (48)
’21 (11) (13) (11) (12) (48)
’20 (4) (7) (5) (5) (22)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — 198 198 198 0.0%
Gross margin, % — — — 0.00 0.00 0.00 0.00 — — — 0.00 0.0 pt
EBT (15) (21) (22) (26) (39) (55) (69) (86) (110) (360) (627) +42.6%
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
Net income (15) (21) (22) (26) (39) (55) (69) (86) (110) (360) (627) +42.6%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings (0.90) (0.79) (0.38) (0.36) (0.54) (0.71) (0.90) (0.91) (1.01) (3.19) (5.40) +15.1%
Cash flow (0.68) (0.57) (0.33) (0.34) (0.30) (0.62) (0.63) (0.78) (0.81) (2.47) (3.92) +15.4%
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.68) (0.57) (0.33) (0.34) (0.30) (0.62) (0.63) (0.78) (0.81) (2.47) (3.92) +15.4%
Book value 0.49 0.52 5.17 3.85 3.37 2.62 1.89 3.69 8.07 5.67 4.99 +31.2%
Shares, m 16 26 58 72 73 77 77 94 109 113 116 +24.0%
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow (11) (15) (19) (25) (22) (48) (48) (73) (88) (279) (463) +43.1%
Capex — — — — — — — — — — — —
Free cash flow (11) (15) (19) (25) (22) (48) (48) (73) (88) (279) (463) +43.1%
Balance, $m
Balance, $m Working capital 7 13 298 277 244 202 145 348 880 639 839 +63.9%
Net debt (10) (17) (302) (276) (248) (202) (155) (362) (903) (706) (709) +60.7%
Shareholders’ equity 8 13 298 277 244 202 145 348 880 639 589 +62.6%
Returns, %
Returns, % ROA (98.29) (112.27) (13.60) (8.79) (14.61) (23.54) (36.32) (31.99) (17.22) (44.29) (73.07) +54.0 pt
ROIC 0.00 0.00 0.00 (1,379.43) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (175.71) (191.36) (14.18) (8.97) (15.15) (24.65) (39.67) (34.79) (17.90) (47.34) (96.37) +128.4 pt
People
People Employees 12 14 18 16 20 18 21 27 36 53 — +17.9%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated 2 Nov 2026

Viking Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ACAD ACADIA Pharmaceuticals Inc. $3.7B 10.0× 33.4× +22.85% (above 0%: growing) −27.91% (below 0%: shrinking) +141.15% (above 0%: growing) 89.75% 20.95% Compare
XENE Xenon Pharmaceuticals Inc. $3.7B — (loss-making) — (loss-making) +100.70% (above 0%: growing) n/m −48.57% (below 0%: shrinking) 100.00% 0.00% Compare
IRON Disc Medicine, Inc. $3.5B — (loss-making) — — n/m +7.83% (above 0%: growing) 0.00% 0.00% Compare
PBLS Parabilis Medicines, Inc. $3.4B — (loss-making) — — n/m — 100.00% (34,382.43%) Compare
TARS Tarsus Pharmaceuticals, Inc. $3.3B — (loss-making) — (loss-making) +63.92% (above 0%: growing) n/m −144.14% (below 0%: shrinking) 92.86% (340.29%) Compare
VKTX Viking Therapeutics, Inc. $3.3B — (loss-making) — — n/m −47.01% (below 0%: shrinking) 0.00% 0.00%
ELVN Enliven Therapeutics, Inc. $3.3B — (loss-making) — — n/m −8.34% (below 0%: shrinking) 0.00% 0.00% Compare
DYN Dyne Therapeutics, Inc. $3.2B — (loss-making) — — n/m −39.08% (below 0%: shrinking) 0.00% 0.00% Compare
CELC Celcuity, Inc. $3.1B — (loss-making) — — n/m −53.27% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $3.4B — — +63.92% — −39.08% 44.88% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 1 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 21.27m 7.50m 624.87
2024 14.30m 106.75m 714.74
2023 12.63m 36.95m 330.55
2022 5.41m 13.26m 166.96
2021 4.06m 2.81m 81.71

Ownership

Directors and executive officers, together 5.30%
FMR LLC 5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Viking Therapeutics, Inc. (VKTX) Latest News

2 Nov

Impact 3 · · The Motley Fool

30 Oct

Impact 3 · · Zacks

29 Oct

Impact 4 · · Zacks earnings
Impact 4 · · Zacks
Impact 4 · · Simply Wall St.
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby

28 Oct

Impact 4 · · Stocktwits
Impact 4 · · Investing.com
Impact 4 · · PR Newswire

26 Oct

Impact 3 · · Zacks

25 Oct

Impact 4 · · 24/7 Wall St.

23 Oct

Impact 3 · · Zacks

22 Oct

Impact 3 · · Zacks

21 Oct

Impact 3 · · PR Newswire

20 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · The Motley Fool
Impact 4 · · The Motley Fool
Impact 4 · · Zacks
Impact 3 · · Simply Wall St.

18 Oct

Impact 4 · · The Motley Fool

16 Oct

Impact 3 · · Zacks

15 Oct

Impact 4 · · Zacks

14 Oct

Impact 4 · · Stocktwits
Impact 4 · · PR Newswire
Impact 4 · · Simply Wall St.

12 Oct

Impact 4 · · The Motley Fool

10 Oct

Impact 4 · · The Motley Fool

9 Oct

Impact 3 · · Zacks

VKTX metrics, ten years each

stockrow.com/VKTX · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com